Loading...
Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide
In patients with metastatic castrate‐resistant prostate cancer (mCRPC), circulating tumor DNA (ctDNA) analysis offers novel opportunities for the development of non‐invasive biomarkers informative of treatment response with novel agents targeting the androgen‐receptor (AR) pathway, such as abiratero...
Na minha lista:
| Udgivet i: | Int J Cancer |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
John Wiley and Sons Inc.
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6099279/ https://ncbi.nlm.nih.gov/pubmed/29574703 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.31397 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|